Improving Pediatric Beta-Lactam Allergy Diagnosis Through Risk Stratification

Accurate pediatric beta-lactam allergy diagnosis remains a cornerstone of modern antibiotic stewardship. Many children receive an allergy label after developing mild rashes during antibiotic therapy for viral infections. However, research consistently shows that over 90% of these patients are not truly allergic. A recent retrospective study evaluated a risk-stratified approach to improve diagnostic efficiency while maintaining patient safety.

Clinicians evaluated 180 children between the ages of 3 and 18 for suspected hypersensitivity. The researchers stratified patients based on their reaction timing and clinical phenotype. Specifically, moderate-to-high-risk cases with a history of anaphylaxis underwent skin testing first. In contrast, low-risk cases, such as those with mild maculopapular exanthema (MPE), proceeded directly to an oral drug provocation test (DPT). This direct approach avoids the logistical challenges and discomfort associated with skin testing in younger populations.

The results highlighted a significant disparity in confirmation rates. Hypersensitivity was confirmed in 21.1% of immediate reaction cases but only 3.5% of non-immediate cases. Furthermore, among 57 low-risk children who underwent direct DPT, only two experienced mild, self-resolving skin reactions. No systemic or severe reactions occurred during the study. Consequently, the data supports the safety of bypassing skin tests for children with benign, delayed-onset rashes.

Moreover, the study found no positive reactions in children who initially presented with delayed-onset urticaria occurring more than six hours after dosing. Therefore, a detailed clinical history is essential to identify these low-risk individuals. Implementing direct oral DPT more widely can facilitate timely delabeling and prevent the unnecessary use of broad-spectrum antibiotics. Ultimately, this strategy improves clinical outcomes and reduces healthcare costs by ensuring children receive the most appropriate first-line treatments.

Frequently Asked Questions

What are considered low-risk phenotypes for beta-lactam allergy?

Low-risk phenotypes include mild maculopapular exanthema (MPE) or benign delayed-onset urticaria that occurs more than six hours after the initial dose and lasts for at least 24 hours.

Is it safe to perform a drug provocation test without skin testing?

Yes, for children identified as low-risk based on a detailed clinical history, direct oral drug provocation testing is safe and efficient. Research shows it rarely leads to severe reactions in this specific group.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Sancaklı Ö et al. Direct drug provocation testing for the diagnosis of low-risk pediatric beta-lactam allergy: A risk-stratified retrospective study. Pediatr Allergy Immunol. 2026 Apr undefined. doi: 10.1111/pai.70327. PMID: 41922919.

Wong T et al. Beta-lactam allergy in the paediatric population. Paediatr Child Health. 2020;25(1):62-73. doi: 10.1093/pch/pxz153.

Moral L et al. Direct oral drug provocation test is safe and effective for beta-lactam allergy delabeling in children. Pediatr Allergy Immunol. 2024;35(2):e14088. doi: 10.1111/pai.14088.